Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | LYPLA1 | O75608 | 1/20 | 0.31 |
| ▸ | LYPLA2 | O95372 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
| ▸ | RXRB | P28702 | 1/20 | 0.30 |
| ▸ | RXRG | P48443 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12550602 | 0.84 | EPHX2 (0.47) | CYP2D6KCNH2HRH3EPHX2HSD11B1 | |
| SCHEMBL15448194 | 0.83 | CYP2D6 (0.47) | CYP2D6KCNH2HRH3EPHX2HSD11B1 | |
| SCHEMBL1104719 | 0.83 | CYP2D6 (0.47) | CYP2D6KCNH2HRH3EPHX2HSD11B1 | |
| SCHEMBL12550696 | 0.81 | CYP2D6 (0.31) | CYP2D6KCNH2HRH3 | |
| SCHEMBL1104702 | 0.81 | CYP2D6 (0.53) | CYP2D6KCNH2HRH3EPHX2HSD11B1 | |
| SCHEMBL14136826 | 0.74 | CYP2D6 (0.39) | CYP2D6KCNH2HRH3EPHX2GAA | |
| SCHEMBL24777816 | 0.73 | CYP2D6 (0.38) | CYP2D6KCNH2HRH3EPHX2HSD11B1 | |
| Hydrochloric Acid SCHEMBL14136820 | 0.73 | CYP2D6 (0.38) | CYP2D6KCNH2HRH3EPHX2GAA | |
| SCHEMBL12550595 | 0.72 | EPHX2 (0.41) | CYP2D6KCNH2HRH3EPHX2HSD11B1 | |
| SCHEMBL15298469 | 0.71 | ATM (0.38) | CYP2D6KCNH2HRH3EPHX2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110129549-A1 | TRICYCLIC BENZO[5,6]CYCLOHEPTA[1,2-B]PYRIDINE DERIVATIVES AND USES THEREOF | CONCERT PHARMACEUTICALS, INC. | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110129549-A1 | TRICYCLIC BENZO[5,6]CYCLOHEPTA[1,2-B]PYRIDINE DERIVATIVES AND USES THEREOF | FDPS, LONP1, DHPS | CYP2D6 172/4885KCNH2 3991/4885HRH3 3480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.